Reaction
Tumour Perforation reporting signals
As of the last recalculation, Tumour Perforation appears in 307 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is OXALIPLATIN (PRR 117.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Oxaliplatin | 91 | 117.8 | 117.9 |
| Bevacizumab | 119 | 105.7 | 105.9 |
| Capecitabine | 76 | 74.5 | 74.6 |
| Irinotecan Hydrochloride | 13 | 71.5 | 71.6 |
| Granisetron Hydrochloride | 10 | 67.1 | 67.1 |
| Fluorouracil Cream, 0.5% | 55 | 59.3 | 59.4 |
| Fluorouracil | 55 | 58.5 | 58.5 |
| Regorafenib | 8 | 47.9 | 48.0 |
| Granisetron | 7 | 46.3 | 46.3 |
| Panitumumab | 8 | 35.5 | 35.5 |
| Atezolizumab | 14 | 25.6 | 25.6 |